Entrada Therapeutics announced its financial results for Q2 2026, highlighting progress in its Duchenne muscular dystrophy (DMD) clinical programs. The company completed enrollment for key study cohorts and expects multiple data readouts between late 2026 and early 2027, including safety and efficacy results for its ENTR-601-44 and ENTR-601-45 candidates. Additionally, Entrada's collaboration with Vertex on the VX-670 program for myotonic dystrophy type 1 (DM1) is progressing with data expected in H2 2026. With a cash position of $223 million, the company is funded into Q3 2027 and aims to advance its pipeline with potential new treatments for neuromuscular and inherited retinal diseases.
Ethereum price surged past its $2,550–$2,575 resistance zone on September 20, now using this level as support. The token climbed over 75% from $1,510 to $2,650 in three months, marking its second-best quarterly gain on record. Institutional ETF inflo...
Polymarket, a major player in the prediction market sector, is under investigation by the Commodity Futures Trading Commission (CFTC) after a $10 million attempted fraud was uncovered on its U.S. betting platform. The company reportedly rejected 80% ...
In 2024, the AI power trade, which saw surging interest in stocks of power suppliers and equipment makers, has cooled off since June despite rising earnings and positive guidance. This paradox exists because power remains a critical bottleneck for da...
Shiba Inu's price surged over 5% in 24 hours, reclaiming levels above $0.0000055 amid a broader crypto market upswing. However, on-chain data reveals a large net inflow of 144 billion SHIB tokens to exchanges, indicating sellers dominate and may trig...
This week, crypto markets experienced high volatility with Bitcoin reclaiming $80,000 and Ethereum and Solana rallying due to short covering and renewed risk appetite. Altcoins outperformed late in the week, led by Akedo (AKE) which surged 400%, driv...
